Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 4/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778417 | 0.76 | AKT1 (0.54) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL4779221 | 0.72 | HDAC8 (0.56) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL4773603 | 0.72 | HDAC8 (0.64) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL27564787 | 0.72 | GRM1 (0.67) | GRM1 | |
| SCHEMBL4739742 | 0.69 | HDAC8 (0.54) | HDAC8DPP4HDAC1HDAC3HDAC2 | |
| SCHEMBL4739747 | 0.69 | HDAC8 (0.54) | HDAC8DPP4HDAC1HDAC3HDAC2 | |
| SCHEMBL4908205 | 0.69 | SCD5 (0.37) | GRM1DPP4AKT1 | |
| SCHEMBL4773301 | 0.68 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL4908327 | 0.68 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL4772278 | 0.67 | HDAC8 (0.60) | HDAC8HDAC1HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | HDAC8 16/4885GRM1 1268/4885DPP4 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.